Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466549 | 0.88 | TSHR (0.44) | SMN1; SMN2CYP1A2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL12466625 | 0.85 | KMT2A (0.45) | SMN1; SMN2CYP1A2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL12466297 | 0.84 | TSHR (0.42) | KMT2AGAATSHRHPGDMAPT | |
| SCHEMBL970569 | 0.82 | KMT2A (0.45) | SMN1; SMN2MAPK1KMT2AMEN1TSHR | |
| SCHEMBL4527898 | 0.80 | KMT2A (0.49) | KMT2AGAAMEN1TSHRHPGD | |
| SCHEMBL12466795 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2CYP1A2CYP2C9MAPK1KMT2A | |
| SCHEMBL4046233 | 0.78 | TSHR (0.53) | MAPK1KMT2AGAAMEN1TSHR | |
| SCHEMBL12466677 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP1A2CYP2C9MAPK1KMT2A | |
| SCHEMBL12466478 | 0.75 | KMT2A (0.39) | SMN1; SMN2MAPK1KMT2AGAAMEN1 | |
| SCHEMBL7998275 | 0.75 | HRH3 (0.48) | CYP1A2CYP2C9CYP2D6TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104178-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 山东绿叶制药有限公司 | 2023-06-15 | — | — | WO | disclosed |
| EP-2668190-B1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-17 | — | — | EP | disclosed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2668190-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| WO-2012101032-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | SMN1; SMN2 4026/4885CYP1A2 3241/4885CYP2C9 3425/4885 |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | SMN1; SMN2 4265/4885CYP1A2 2178/4885CYP2C9 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.